Our award for statistical excellence in the pharmaceutical industry is made jointly with the Royal Statistician Society (RSS) every year.
The aim of the award is to recognise an outstanding level of influence in the application of an existing statistical practice, or an innovation, that has strengthened the quality and efficiency of investigations in the pharmaceutical industry.
Read about last year's winner here.
We are looking for entries that have demonstrated one or more of the following:
Nominees can be based anywhere in the world and do not need to be a member of PSI or the RSS. The award will be presented at the annual PSI AGM.
Lisa Hampson was presented with the PSI / RSS Award for Statistical Excellence in the Pharmaceutical Industry. She was nominated for her work on: "Improving the assessment of the probability of success in drug development: A holistic framework encompassing statistical significance, regulatory approval, and market access". Distinguishing it from existing approaches, this framework adopts a broader definition of ‘success’ that bridges statistical significance, clinical relevance, benefit-risk assessments, regulatory alignment, and market access as well as technical development, quality and compliance considerations.
This approach was endorsed by the Novartis Innovation Management Board, chaired by the company’s CEO, in September 2020 and has since then formally been rolled out across the entire portfolio.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
An informal event starting with a short talk and then going into breakout rooms to connect with others from the industry. Aimed at those who have recently joined the industry looking to expand their network.
Learn more about the different techniques and applications propensity scores and the advantages and disadvantages of different methods.
Drs Qiu and Wenren will present their investigations on EC50 estimation based on multi-donor dose-response data via different approaches.
This role is for a senior functional team member supporting Biostatistics activities on assigned Clinical Development, Enterprise Data & Analytics, and QDS projects.
